Application of recombinant trichina thioredoxin peroxidase 2 in preparation of medicine for improving and / or preventing obesity

By inhibiting macrophage polarization through recombinant Trichinella spiralis thioredoxin peroxidase 2 (rTsTPX2), the shortcomings of existing obesity treatments have been overcome, achieving safe and effective improvement of obesity and metabolic disorders, reducing weight and blood lipids, and alleviating liver damage.

CN122440797APending Publication Date: 2026-07-24ZHENGZHOU UNIV
1 Cites 0 Cited by

Patent Information

Application Number
CN202610919682.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-06-24
Publication Date
2026-07-24

AI Technical Summary

Technical Problem

Existing treatments for obesity have drawbacks such as significant side effects, limited long-term efficacy, and easy rebound after discontinuation of medication. Furthermore, there is a lack of novel anti-obesity drugs with clear mechanisms of action and high safety. The application of Trichinella spiralis thioredoxin peroxidase 2 in obesity and metabolic diseases has not been reported.

Method used

Using recombinant Trichinella spiralis thioredoxin peroxidase 2 (rTsTPX2) as the sole active ingredient, this study uses intraperitoneal immunotherapy to inhibit macrophage polarization towards the pro-inflammatory M1 type and promote M2 polarization, thereby improving adipose tissue and systemic chronic low-grade inflammation, and preparing a treatment to improve and/or prevent obesity-related diseases.

Benefits of technology

rTsTPX2 significantly reduces weight and body fat, improves glucose metabolism, lowers blood lipid levels, alleviates fatty liver and liver function damage, and provides comprehensive intervention for obesity and metabolic disorders, avoiding the side effects and risks of complex ingredients of traditional drugs.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses an application of recombinant trichina thioredoxin peroxidase 2 (rTsTPX2) in preparation of medicines for improving and / or preventing obesity, relates to the technical field of biological medicines, and finds that the recombinant trichina thioredoxin peroxidase 2 (rTsTPX2) has a remarkable effect of improving obesity and related metabolic disorders for the first time. Compared with the prior art, the application range of the rTsTPX2 is expanded, the known anti-parasitic vaccine application is expanded to the field of obesity and metabolic disease prevention and treatment, and a brand new candidate molecule is provided for obesity treatment. The rTsTPX2 can effectively improve adipose tissue and whole body chronic low-degree inflammation by inhibiting macrophages from proinflammatory M1 type polarization and M2 type polarization, further improve glucose and lipid metabolism disorder and relieve obesity phenotype from the pathologic root, and is different from the action mode that a traditional weight-losing medicine only inhibits appetite or reduces lipid absorption.
Need to check novelty before this filing date? Find Prior Art